How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Spina Bifida Treatment Market
- By Treatment Type: Surgical Treatment, Physical Therapy, Occupational Therapy, Assistive Devices, Pharmacological Treatment
- By Surgical Procedure: Prenatal Surgery, Postnatal Surgery, Shunt Placement, Tethered Cord Release, Orthopedic Surgery
- By Assistive Devices: Orthotic Devices, Wheelchairs, Walking Aids, Bladder Management Devices, Communication Aids
- By Patient Age Group: Neonates, Pediatrics, Adolescents, Adults
- By Complication Management: Hydrocephalus Management, Urinary Tract Infection Management, Mobility Impairment Management, Skin Care Management
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Treatment leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Spina Bifida Treatment Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Surgical Procedure 5
Assistive Devices 5
Patient Age Group 4
Complication Management 4
Companies profiled
Medtronic plc
Stryker Corporation
Zimmer Biomet Holdings Inc.
NuVasive Inc.
Globus Medical Inc.
Orthofix International N.V.
DePuy Synthes (Johnson & Johnson)
Integra LifeSciences Holdings Corporation
Mazor Robotics Ltd. (acquired by Medtronic)
K2M Group Holdings
Inc. (acquired by Stryker)
Abbott Laboratories
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Zimmer Biomet Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →NuVasive Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Globus Medical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Orthofix International N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →DePuy Synthes (Johnson & Johnson)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Integra LifeSciences Holdings Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mazor Robotics Ltd. (acquired by Medtronic)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →K2M Group Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (acquired by Stryker)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Abbott Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Boston Scientific Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →B. Braun Melsungen AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Siemens Healthineers AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →GE Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,709M by 2033 · 11.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Treatment47.6
- Physical Therapy12.8
- Occupational Therapy12.2
- Assistive Devices11.0
- Pharmacological Treatment16.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,096M → $2,459M · 10.6%
Europe$763.6M → $1,685M · 10.4%
Asia Pacific$697.2M → $1,481M · 9.9%
Latin America$431.6M → $926.8M · 10.0%
Middle East and Africa$332.0M → $790.3M · 11.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.052026
11.082027
11.082028
11.102029
11.102030
11.122031
11.122032
11.142033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc22.1
- Stryker Corporation21.5
- Zimmer Biomet Holdings Inc.5.5
- NuVasive Inc.9.7
- Globus Medical Inc.6.7
- Orthofix International N.V.6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type19.3%
Surgical Procedure17.0%
Assistive Devices24.5%
Patient Age Group19.0%
Complication Management20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.5
- Europe22.9
- Asia Pacific20.2
- Latin America12.6
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 74 | 90 | 99 | 89 | 81 | 93 | 88 |
| Stryker Corporation | 81 | 89 | 69 | 72 | 82 | 76 | 78 |
| Zimmer Biomet Holdings Inc. | 64 | 85 | 74 | 79 | 67 | 75 | 74 |
| NuVasive Inc. | 65 | 69 | 73 | 77 | 68 | 58 | 68 |
| Globus Medical Inc. | 58 | 62 | 69 | 64 | 72 | 63 | 65 |
| Orthofix International N.V. | 54 | 70 | 48 | 59 | 55 | 46 | 55 |
| DePuy Synthes (Johnson & Johnson) | 65 | 48 | 41 | 45 | 53 | 50 | 50 |
| Integra LifeSciences Holdings Corporation | 57 | 51 | 38 | 46 | 36 | 55 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Stryker Corporation
- Zimmer Biomet Holdings Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Stryker Corporation | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Zimmer Biomet Holdings Inc. | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| NuVasive Inc. | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Globus Medical Inc. | − | ◐ | ◐ | − | ◐ | ◐ |
| Orthofix International N.V. | − | − | − | ◐ | ◐ | − |
| DePuy Synthes (Johnson & Johnson) | − | − | ◐ | − | ◐ | − |
| Integra LifeSciences Holdings Corporation | ◐ | − | ◐ | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc88
2Stryker Corporation78
3Zimmer Biomet Holdings Inc.74
4NuVasive Inc.68
5Globus Medical Inc.65
6Orthofix International N.V.55
7DePuy Synthes (Johnson & Johnson)50
8Integra LifeSciences Holdings Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcStryker Corporation
Challenger2
Strong scale, closing on the leaders.
Zimmer Biomet Holdings Inc.NuVasive Inc.
Contender1
Focused players with pockets of strength.
Globus Medical Inc.
Niche3
Specialists in a single segment or region.
Orthofix International N.V.DePuy Synthes (Johnson & Johnson)Integra LifeSciences Holdings Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Spina Bifida Treatment Market — a $461M beachhead inside a $6.39B market.
Beachhead (SOM)$461Mobtainable near-term
Serviceable (SAM)$2.44Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Surgical Treatment
Best fit — highest urgency & budget in Treatment Type.
Economic buyer76 fit
Physical Therapy
Strong fit — clear ROI and a fast path to value.
End user70 fit
Occupational Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Surgical Procedure & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Assistive Devices
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Spina Bifida Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation11%
Closed-won7%
$17.1KCAC
$60KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Spina Bifida Treatment Market is a durable-growth opportunity — $6.34B by 2033, compounding at 7.7%.
TAM · 2025$3.50Btoday
TAM · 2033$6.34Bforecast
CAGR7.7%2027–2033
Cumulative$43.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.34BTotal addressable market
SAM$2.45BServiceable available market
SOM$474MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.7% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.34BLarge & growingTAM by 2033 at 7.7% CAGR
$2.45BServiceable nowreachable with today’s model
$474MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.95BBear5.0% CAGR
$6.34BBase7.7% CAGR
$8.12BBull10.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Surgical Procedure optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Spina Bifida Treatment Market — a $1.13B market by 2033. Plan: grow share from 8.0% to 16.1%.
Market size · 2033$1.13Btotal addressable
Market CAGR8.5%2027–2033
Target share16.1%from 8.0% today
Revenue ambition$182Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 16.1% | Behind |
| Revenue | $85M | $182M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 36.5% | 43.9% | On track |
| Customer retention | 85.0% | 95.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Surgical Procedure capability
A defensible second engine — invest in Surgical Procedure to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Surgical Procedure
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $25M capacity & capability investment
- Greenlight bolt-on M&A in Surgical Procedure
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Spina Bifida Treatment Market conversation — a $4.54B market you can size, segment and defend in minutes.
Market size · 2033$4.54Btotal opportunity
Growth7.7%CAGR to 2033
Addressable buyers1,511+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Medtronic plcStryker CorporationZimmer Biomet Holdings Inc.NuVasive Inc.Globus Medical Inc.Orthofix International N.V.DePuy Synthes (Johnson & Johnson)Integra LifeSciences Holdings Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Spina Bifida Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Spina Bifida Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Spica Prunellae Extract Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportSphygmomanometer Cuffs Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportSphingosine-1-Receptor Modulators Drugs Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportSphingosine 1-Phosphate Receptor (S1PR) Modulator Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportSphingomyelin Profiling Service Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSphingolipidoses Treatment Market
Market size, share, segmentation and regional forecast.
$618M market · 2025 base year
View reportSphincterotomy Tool Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportSphincterotomy Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportSpherical Shadowless Light Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportSpherical IOL Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportSpherical Aberration Corrected Transmission Electron Microscope Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportSperm Washing Medium Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.